Welcome to the STAMPEDE website.
We will be adding regular updates about the trial and have made all of the trial documentation available for you to download. Please check the site regularly and add us to your favourites!
Prostate cancer accounts for around one fifth of all male cancers. In the UK there are around 47,000 new cases each year and around 10,800 deaths. Most men with prostate cancer are given hormone therapy and this is often effective for a short time at stopping the tumour growing. However in most cases over time the tumour will start to grow again.
The aim of this trial is to try to prevent the tumour re-growth by adding other treatment to the hormone therapy. The trial is currently assessing abiraterone and enzalutamide in combination with hormone therapy or radiotherapy (newly diagnosed metastatic patients only) in combination with hormone therapy.
A number of hospitals throughout the UK and Switzerland are participating in the Stampede Study. Please find a map showing the location of these hospitals here (Stampede map)
Please ensure that all patients taking abiraterone as part of their research treatment have the required additional safety monitoring as outlined in the STAMPEDE protocol.
Stampede has recruited over 9,072 patients to date, with 397 patients recruited to the "metformin comparison". The 9000th patient was recruited at Royal Bolton in April this year. Congratulations to all of the research teams who have helped with this great achievement! Thank you for your hard work and dedication, it is very much appreciated!
For the purposes of the STAMPEDE trial, a PSA progression value calculator has been created to allow sites to calculate a unique threshold PSA value for biochemical failure for each patient, referred to as the PSA progression value. In the past, research staff have received Progression Letters or contacted the STAMPEDE trial team to obtain this value. However the PSA progression calculator allows research staff to determine the Progression Value themselves, by entering the patient’s PSA results from randomisation to week 24, and printing a copy of the calculation for the patient’s records.
We hope with the launch of this calculator it will be easier for you to track a patient’s PSA record and progression status. Additionally we welcome any feedback or suggestions for improvement!
For more details click here.
We are pleased to inform you of the survival results from the “celecoxib comparisons” have now been published in The Journal of Clinical Oncology. A link to the Open Access paper is provided here for your information, along with an editorial relating to the results:
The Journal of Clinical Oncology paper
Open Access paper: http://ascopubs.org/doi/abs/10.1200/jco.2016.69.0677
The “M1|RT comparison” opened to recruitment in January 2013 and has progressed through all its pre‑planned
interim analyses. The IDMC has also recently had the opportunity to carry out an annual review of the data.
The TMG and TSC have had the opportunity to discuss recruitment progress and have agreed that this comparison
will close to recruitment in Sep-2016.
All randomisations to Arm H will therefore stop on Friday 02-Sep-2016 at 5pm.
The closure to recruitment to Arm H will shortly be followed by the launch of the “metformin comparison”
(Arm A vs Arm K) on Monday 05-Sep-2016.
We hope that this timeline will allow for a seamless change between the closure of one comparison and the
opening of a new one with minimal impact and administrative burden to centres.
The survival results from the “original comparisons” have been now published on The Lancet. A copy of the Open Access paper can be viewed on the MRC CTU website and a link is provided here for your information:
The Lancet paper
A meta-analysis of the STAMPEDE results and similar trials has also been published in The Lancet Oncology
Two briefing papers have also been put together summarising the findings from the “original comparison” as well as the recommendations that followed. These can be found here
Finally, two short films (15 min) have been produced aimed at patients, the public and health workers to explore and discuss the results
Results film for patients
Results film for health workers
Thank you for all your support and for help making these practice-changing results available to the clinical community.